Therapeutic Potential of Ranibizumab in Corneal Neovascularization

Publication date: Available online 9 June 2017 Source:Trends in Pharmacological Sciences Author(s): Marianne L. Shahsuvaryan Ranibizumab is a humanized, affinity-matured vascular endothelial growth factor (VEGF) antibody fragment that neutralizes all isoforms of VEGF and is FDA approved for use in ophthalmology. Recently it was suggested that ranibizumab may be useful in the treatment of corneal neovascularization, but in reality this therapy is not yet evidence based.
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research